HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Researchers Suggest Supplement Sales Grow As Consumers Ignore Studies

This article was originally published in The Rose Sheet

Executive Summary

US adults' use of vitamins and supplements remained at around 52% from 1999 through 2012, information that should point lawmakers to ensuring more information is made known to consumers about studies questioning the products’ benefit, researchers say a JAMA study and editorial.

You may also be interested in...



Supplement Industry Critics On Agenda For FDA's Ingredient List Meeting

FDAs Oct. 3 meeting agenda includes Pieter Cohen, Harvard Medical School professor; Consumers Union Programs Director Chuck Bell; Laura MacCleery, Center for Science in the Public Interest regulatory affairs director; and Stephanie Scarmo, Pew Charitable Trusts Health Care Products Project officer.

Mineral Supplement, Superfood Sales Rise As Multivitamin Use Slips

Mineral supplements and vitamins are growing but multivitamins are waning in popularity, says Packaged Facts’ David Sprinkle. Though fortified food products are eating into nutritional supplement sales, the sales are steadily climbing and are anticipated to exceed $16bn in 2018.

FDA Warnings Mark Tip Of Iceberg For Stimulant-Spiked Supplements – Study

Researchers' "particular concern" about the stimulant oxilofrine in sports nutrition supplements is that more than 1m youth athletes use the products. Based on labeling, adolescents could consume three times the highest pediatric dose allowed where oxilofrine is approved as a drug.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS108615

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel